Skip to main content
SpringerLink
Log in

Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

The possible effect of sulfasalazine, 5-aminosalicylic acid, and acetyl-5-aminosalicylic acid on endogenous arachidonic acid release and metabolism was studied in human polymorphonuclear leukocytes (PMNs). A newin vitro assay was used by which [1-14C]arachidonic acid is incorporated by purified peripheral PMNs until steady state was obtained (5 hr). After preincubation with the test drugs prior to activation with calcium ionophore A23187, the released eicosanoids were isolated by extraction and thin-layer chromatography (TLC) and quantitated by autoradiography and laser densitometry. Median drug concentrations needed for 50% inhibition of leukotriene B4 and 5-hydroxyeicosatetraenoic acid (5-HETE) release was 4–5 mM (range 1–9 mM) for both sulfasalazine and 5-aminosalicylic acid. The acetylated derivative of 5-aminosalicylic acid was ineffective.

The present data suggest that inhibition of arachidonic acid lipoxygenation may be an essential action of sulfasalazine and its active metabolite, 5-aminosalicylic acid. Interference with lipoxygenase enzymes, rather than a steroid-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Peppercorn MA: Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med 3:377–386, 1984

    Google Scholar 

  2. Misiewicz JJ, Lennard-Jones JE, Connell AM, Baron JH, Jones FA: Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1:185–188, 1965

    Google Scholar 

  3. Dissanayake AS, Truelove SC: A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine. Gut 14:923–926, 1973

    Google Scholar 

  4. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, Singleton JW: National cooperative Crohn's disease study: Results of drug treatment. Gastroenterology 77:847–869, 1979

    Google Scholar 

  5. Donowitz M: Arachidonic acid metabolites and their role in inflammatory bowel disease. Gastroenterology 88:580–587, 1985

    Google Scholar 

  6. Das KM, Dubin R: Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1:406–425, 1976

    Google Scholar 

  7. Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892–895, 1977

    Google Scholar 

  8. Van Hees PAM, Bakker JH, Van Tongeren JHM: Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study to determine the active moiety of sulphasalazine. Gut 21:632–635, 1980

    Google Scholar 

  9. Das KM, Eastwood MA, McManus JPA, Sircus W: Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 289:491–495, 1973

    Google Scholar 

  10. Taffet SL, Das KM: Sulfasalazine: Adverse effects and desensitization. Dig Dis Sci 28:833–842, 1983

    Google Scholar 

  11. Nielsen OH: Sulfasalazine intolerance: A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 17:389–393, 1982

    Google Scholar 

  12. Meese CO, Fischer C, Klotz U: Is acetylation of 5-aminosalicylic acid reversible in man. Br J Clin Pharmacol 18:612–615, 1984

    Google Scholar 

  13. Sharon P, Stenson WF: Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86:453–460, 1984

    Google Scholar 

  14. Boughton-Smith NK, Hawkey CJ, Whittle BJR: Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C]arachidonic acid by human colonic mucosa. Gut 24:1176–1182, 1983

    Google Scholar 

  15. Lauritsen K, Hansen J, Bytzer P, Bukhave K, Rask-Madsen J: Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibriumin vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Gut 25:1271–1278, 1984

    Google Scholar 

  16. Ligumsky M, Karmeli F, Sharon P, Zor U, Cohen F, Rachmilewitz D: Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 81:444–449, 1981

    Google Scholar 

  17. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J: Effects of systemic prednisolone on arachidonic acid metabolites determined by equilibriumin vivo dialysis of rectum in severe relapsing ulcerative colitis. Gastroenterology 88:1466, 1985 (abstract)

    Google Scholar 

  18. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J: Effect of topical 5-aminosalicylic acid (5-ASA) and prednisolone on prostaglandin (PG)E2 and leukotriene (LT)B4 levels determined by equilibriumin vivo dialysis of rectum in relapsing ulcerative colitis (UC). Gastroenterology 88:1466, 1985 (abstract)

    Google Scholar 

  19. Gould SR, Brash AR, Conolly ME, Lennard-Jones JE: Studies of prostaglandins and sulphasalazine in ulcerative colitis. Prostaglandins Med 6:165–182, 1981

    Google Scholar 

  20. Rampton DS, Sladen GE: Prostaglandin synthesis inhibitors in ulcerative colitis: Flurbiprofen compared with conventional treatment. Prostaglandins 21:417–425, 1981

    Google Scholar 

  21. Hawkey CJ, Rampton DS: Benoxaprofen in the treatment of active ulcerative colitis. Prostaglandins Med 10:405–409, 1983

    Google Scholar 

  22. Rampton DS, McNeil NI, Sarner M: Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut 24:187–189, 1983

    Google Scholar 

  23. Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: Studies with the sulphasalazine metabolitesn-acetylaminosalicylic acid, 5-aminosalicylic acid, and sulfapyridine. Eur J Clin Pharmacol 26:449–451, 1984

    Google Scholar 

  24. Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol 32:170–172, 1983

    Google Scholar 

  25. Stenson WF, Lobos E: Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 69:494–497, 1982

    Google Scholar 

  26. Nielsen OH, Bukhave K, Ahnfelt-Rønne I, Elmgreen J: Arachidonic acid metabolism in human neutrophils. Lack of effect of cyclosporine A. Int J Immunopharmacol 8:419–426, 1986

    Google Scholar 

  27. Böyum A: Isolation of leucocytes from human blood. Scand J Clin Invest 21(Suppl 97):9–29, 1968

    Google Scholar 

  28. Folch J, Lees M, Sloane-Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509, 1957

    Google Scholar 

  29. Flower RJ, Blackwell GJ: Antiinflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 278:456–459, 1979

    Google Scholar 

  30. Hawkey CJ, Boughton-Smith NK, Whittle BJR: Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig Dis Sci 30:1161–1165, 1985

    Google Scholar 

  31. Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, Flachs H: 5-Aminosalicyclic acid in a slow-release preparation: Bioavailability, plasma level, and excretion in humans. Gastroenterology 82:1062–1070, 1982

    Google Scholar 

  32. Lauritsen K, Hansen J, Ryde M, Rask-Madsen J: Colonic azodisalicylate metabolism determined byin vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 86:1496–1500, 1984

    Google Scholar 

  33. Bondesen S, Nielsen OH, Schou JB, Jensen PH, Lassen LB, Binder V, Krasilnikoff PA, Danø P, Hansen SH, Rasmussen SN, Hvidberg EF: Steady-state kinetics of 5-aminosalicylic acid and sulphapyridine during sulphasalazine prophylaxis in ulcerative colitis. Scand J Gastroenterol 21:693–700, 1986

    Google Scholar 

  34. Roediger W, Schapel G, Lawson M, Radcliffe B, Nance S: Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Biochem Pharmacol 35:221–225, 1986

    Google Scholar 

  35. Blackwell GJ, Flower RJ: Inhibition of phospholipase. Br Med Bull 39:260–264, 1983

    Google Scholar 

  36. Binder V, Halskov S, Hvidberg EF, Kristensen E, Riis P, Tougaard L, Willumsen L: A controlled study of 5-acetaminosalicylic acid (5-ac-ASA) as enema in ulcerative colitis. Scand J Gastroenterol 16:1122, 1981 (abstract)

    Google Scholar 

  37. Das KM, Chowdhury JR, Zapp B, Fara JW: Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats. Gastroenterology 77:280–284, 1979

    Google Scholar 

  38. Ahnfelt-Rønne I, Nielsen OH: The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents Actions (in press)

  39. Rhodes JM, Bartholomew TC, Jewell DP: Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut 22:642–647, 1981

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Gastroenterology C, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark

    O. H. Nielsen MD, K. Bukhave CAND. SCIENT., J. Elmgreen MD & I. Ahnfelt-Rønne CAND. SCIENT.

  2. Department of Pharmacology, Leo Pharmaceutical Products, Ballerup, Denmark

    O. H. Nielsen MD, K. Bukhave CAND. SCIENT., J. Elmgreen MD & I. Ahnfelt-Rønne CAND. SCIENT.

Authors
  1. O. H. Nielsen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Bukhave CAND. SCIENT.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Elmgreen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Ahnfelt-Rønne CAND. SCIENT.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by grants from Handelsgartner Ove Villiam Buhl Olesen's and aegtefaelle Edith Buhl Olesen's Foundation, Direktør Jacob Madsen's and hustru Olga Madsen's Foundation, the Foundation of 1870, and the Danish Medical Research Council.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nielsen, O.H., Bukhave, K., Elmgreen, J. et al. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Digest Dis Sci 32, 577–582 (1987). https://doi.org/10.1007/BF01296156

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01296156

Key Words

Search

Navigation